1.Expert consensus on non-surgical treatment for acute lateral ankle sprain (version 2025)
Hui CHE ; Wenge DING ; Shiming FENG ; Xueping GU ; Qinwei GUO ; Jianchao GUI ; Yinghui HUA ; Yuefeng HAO ; Qinglin HAN ; Bo HU ; Xiaojun LIANG ; Guoping LI ; Yunxia LI ; Qi LI ; Yanlin LI ; Xin MA ; Jun MA ; Xudong MIAO ; Jianzhong QIN ; Xiaodong QIN ; Xu SUN ; Kefu SUN ; Weidong SONG ; Dai SHI ; Zhongmin SHI ; Youlun TAO ; Xu WANG ; Youhua WANG ; Liheng WANG ; Anli WANG ; Aiguo WANG ; Weidong WU ; Yajun XU ; Weidong XU ; Renjie XU ; Yongsheng XU ; Tengbo YU ; Lianqi YAN ; Xiaodong YUAN ; Yuan ZHU ; Mingzhu ZHANG ; Hongtao ZHANG ; Xintao ZHANG ; Xiaofei ZHENG
Chinese Journal of Trauma 2025;41(6):517-529
Acute lateral ankle sprain (ALAS) is one of the most common sport injuries, with high incidence, recurrence and disability rates. Currently, exercise rehabilitation-based non-surgical treatment is the primary management approach for ALAS. However, there remain improper practices such as excessive immobilization or uncontrolled activity, which contribute to recurrent sprains and chronic ankle instability, significantly impairing patients′ athletic function and quality of life. To standardize the non-surgical management of ALAS, improve the cure rates, and reduce the recurrence and disability rates, Chinese Sports Rehabilitation Medicine Training Project of Chinese Medical Association, Foot and Ankle Basics and Orthopedics Group, Orthopedic Branch of Chinese Medical Doctor Association, and Sports Medicine Branch of Jiangsu Medical Association organized relevant experts to formulate Expert consensus on non-surgical treatment for acute lateral ankle sprain ( version 2025), following the principles of scientific vigor, practicality, and innovation. Thirteen recommendations were proposed for standardized treatment protocols across different healing phases, aiming to provide references for standard management of ALAS and improve the therapeutic outcomes.
2.Efficacy of Jisheng Shenqi Pills combined with endocrine therapy in alleviating lower urinary tract obstruction symptoms of patients with advanced prostate cancer
Rui DING ; Junjie GUO ; Wenjun ZHOU ; Jianzhong LI ; Jian CHEN
Journal of Clinical Medicine in Practice 2025;29(20):56-59
Objective To observe the therapeutic efficacy of Jisheng Shenqi Pills combined with endocrine therapy in alleviating lower urinary tract obstruction symptoms of patients with advanced prostatecancer(PCa).Methods A total of 68 patients with advanced PCa complicated by lower uri-nary tract obstruction symptoms were randomly divided into observation group and control group,with 34 cases in each group.The control group received endocrine therapy alone,while the observation group received Jisheng Shenqi Pills on the basis of the control group.Both groups underwent a course of 3-month treatment.The total therapeutic effectiveness rate,traditional Chinese medicine(TCM)syndrome scores,maximum urinary flow rate(Qmax),residual urinary volume(RUV),International Prostate Symptom Score(IPSS),prostate-specific antigen(PSA)levels,and Quality of Life(QOL)Scale scores were compared between the two groups.Results The total therapeutic effectiveness rate in the observation group was 94.12%,which was significantly higher than 82.35%in the control group(P<0.05).After treatment,TCM syndrome scores decreased in both groups,with the obser-vation group had significantly lower scores than the control group(P<0.05).Both groups exhibited an increase in Qmax and a decrease in RUV after treatment,with the observation group had significant-ly higher Qmax and lower RUV compared to the control group(P<0.05).PSA level decreased signif-icantly in both groups after treatment(P<0.05),but no significant difference was observed between the two groups(P>0.05).IPSS score was decreased while QOL score was increased in both groups after treatment,with the observation group had significantly lower IPSS score and higher QOL score compared to the control group(P<0.05).Conclusion Jisheng Shenqi Pills combined with endo-crine therapy effectively alleviates urinary obstruction symptoms,improves TCM syndromes,and en-hances quality of life in patients with advanced PCa.
3.Mechanism of immune escape induced by ZBED2 induced PD-L1 expression in hepatocellular carcinoma through glycolysis metabolism
Jinshi HUANG ; Yating DING ; Jianzhong CAO
Chinese Journal of Immunology 2025;41(2):367-373
Objective:To investigate the effect of zine finger BED domain-containing protein 2(ZBED2)on immune escape of hepatocellular carcinoma(HCC)through glycolysis pathway and its potential mechanism.Methods:Expression of ZBED2 in HCC tis-sues and binding sites of them were analyzed in bioinformatics database,the pathway regulated by ZBED2 was analyzed,as well as the correlation between ZBED2 and glycolysis genes.qPCR and Western blot were used to detected expressions of ZBED2 and pro-grammed death-ligand 1(PD-L1)in HCC cells,cell viability was detected by MTT,toxicity of CD8+T cells was detected by cytotoxicity assay,and cytokine expression was detected by ELISA.Extracellular acidification rate(ECAR)and oxygen consumption rate(OCR)were detected by extracellular flow analyzer,glycolytic gene expression was detected by qPCR,and glycolytic index was detected by kit.Expression of CD8+T cell in tumor tissues was detected by immunohistochemical staining.Results:ZBED2 was up-regulated in HCC,overexpression of ZBED2 could promote expression of PD-L1,while inhibit cytotoxicity of CD8+T cells to HCC.Overexpression of ZBED2 inhibited CD8+T cell activity in HCC by activating glycolysis pathway,and further addition of glycolysis inhibitor 2-DG at-tenuated the above results.In vivo experiments showed that ZBED2 knockdown inhibited tumor growth,inhibited PD-L1 expression,while promoted CD8+T cell infiltration in vivo.Conclusion:ZBED2 induces expression of PD-L1 in HCC through glycolytic metabo-lism,and promotes immune escape.
4.Mechanism of immune escape induced by ZBED2 induced PD-L1 expression in hepatocellular carcinoma through glycolysis metabolism
Jinshi HUANG ; Yating DING ; Jianzhong CAO
Chinese Journal of Immunology 2025;41(2):367-373
Objective:To investigate the effect of zine finger BED domain-containing protein 2(ZBED2)on immune escape of hepatocellular carcinoma(HCC)through glycolysis pathway and its potential mechanism.Methods:Expression of ZBED2 in HCC tis-sues and binding sites of them were analyzed in bioinformatics database,the pathway regulated by ZBED2 was analyzed,as well as the correlation between ZBED2 and glycolysis genes.qPCR and Western blot were used to detected expressions of ZBED2 and pro-grammed death-ligand 1(PD-L1)in HCC cells,cell viability was detected by MTT,toxicity of CD8+T cells was detected by cytotoxicity assay,and cytokine expression was detected by ELISA.Extracellular acidification rate(ECAR)and oxygen consumption rate(OCR)were detected by extracellular flow analyzer,glycolytic gene expression was detected by qPCR,and glycolytic index was detected by kit.Expression of CD8+T cell in tumor tissues was detected by immunohistochemical staining.Results:ZBED2 was up-regulated in HCC,overexpression of ZBED2 could promote expression of PD-L1,while inhibit cytotoxicity of CD8+T cells to HCC.Overexpression of ZBED2 inhibited CD8+T cell activity in HCC by activating glycolysis pathway,and further addition of glycolysis inhibitor 2-DG at-tenuated the above results.In vivo experiments showed that ZBED2 knockdown inhibited tumor growth,inhibited PD-L1 expression,while promoted CD8+T cell infiltration in vivo.Conclusion:ZBED2 induces expression of PD-L1 in HCC through glycolytic metabo-lism,and promotes immune escape.
5.Expert consensus on non-surgical treatment for acute lateral ankle sprain (version 2025)
Hui CHE ; Wenge DING ; Shiming FENG ; Xueping GU ; Qinwei GUO ; Jianchao GUI ; Yinghui HUA ; Yuefeng HAO ; Qinglin HAN ; Bo HU ; Xiaojun LIANG ; Guoping LI ; Yunxia LI ; Qi LI ; Yanlin LI ; Xin MA ; Jun MA ; Xudong MIAO ; Jianzhong QIN ; Xiaodong QIN ; Xu SUN ; Kefu SUN ; Weidong SONG ; Dai SHI ; Zhongmin SHI ; Youlun TAO ; Xu WANG ; Youhua WANG ; Liheng WANG ; Anli WANG ; Aiguo WANG ; Weidong WU ; Yajun XU ; Weidong XU ; Renjie XU ; Yongsheng XU ; Tengbo YU ; Lianqi YAN ; Xiaodong YUAN ; Yuan ZHU ; Mingzhu ZHANG ; Hongtao ZHANG ; Xintao ZHANG ; Xiaofei ZHENG
Chinese Journal of Trauma 2025;41(6):517-529
Acute lateral ankle sprain (ALAS) is one of the most common sport injuries, with high incidence, recurrence and disability rates. Currently, exercise rehabilitation-based non-surgical treatment is the primary management approach for ALAS. However, there remain improper practices such as excessive immobilization or uncontrolled activity, which contribute to recurrent sprains and chronic ankle instability, significantly impairing patients′ athletic function and quality of life. To standardize the non-surgical management of ALAS, improve the cure rates, and reduce the recurrence and disability rates, Chinese Sports Rehabilitation Medicine Training Project of Chinese Medical Association, Foot and Ankle Basics and Orthopedics Group, Orthopedic Branch of Chinese Medical Doctor Association, and Sports Medicine Branch of Jiangsu Medical Association organized relevant experts to formulate Expert consensus on non-surgical treatment for acute lateral ankle sprain ( version 2025), following the principles of scientific vigor, practicality, and innovation. Thirteen recommendations were proposed for standardized treatment protocols across different healing phases, aiming to provide references for standard management of ALAS and improve the therapeutic outcomes.
6.Effect of diagnosis and endoscopic minimally invasive treatment of non-cystic congenital pyriform sinus fistula in children
Jiaojiao DING ; Xiumin LU ; Ruipeng BI ; Jianzhong SANG
China Journal of Endoscopy 2024;30(8):74-79
Objective To explore the effect of the diagnosis and endoscopic minimally invasive surgical treatment of non-cystic congenital pyriform sinus fistula(CPSF)in children.Methods Clinical data of 76 children with non-cystic CPSF were retrospectively analyzed from October 2017 to May 2022.Larygoscope,neck color ultrasound,esophageal barium meal,neck CT,and magnetic resonance imaging(MRI)were performed,and temperature-controlled ablation radio-frequency was performed under general anesthesia supported by laryngoscope guidance.Results The internal fistula in the pyriform fossa was seen under laryngoscope.Imaging examination shows that the fistula was connected to the pharynx.Postoperative complications:hoarseness in 3 cases and deciduous tooth loss in 3 cases.After a follow-up period of 12~40 months,there was 1 recurrence in 46 newly treated patients and 1 recurrence in 30 non newly treated patients.No recurrence was observed during the follow-up period after re-endoscopic radiofrequency plasma surgical electrodes plasma cauterization.Conclusion The symptoms of CPSF are non-specific.The discovery of the internal fistula under endoscopy is the gold standard for diagnosis.Ultrasound can be used as the initial screening method for diagnosis.Esophageal barium meal combined with CT examination can improve the diagnostic rate,and MRI can assist in diagnosis.The temperature-controlled ablation radio-frequency technique under supportive laryngoscope has the advantages of safety,minimally invasive,aesthetic,convenient,and repeatable operation,and can be used as the preferred method for the treatment of non-cystic CPSF in children.
7.Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
Yan ZHAO ; Jianzhong ZHANG ; Bin YANG ; Jingyi LI ; Yangfeng DING ; Liming WU ; Litao ZHANG ; Jinyan WANG ; Xiaohong ZHU ; Furen ZHANG ; Xiaohua TAO ; Yumei LI ; Chunlei ZHANG ; Linfeng LI ; Jianyun LU ; Qingchun DIAO ; Qianjin LU ; Xiaoyong MAN ; Fuqiu LI ; Xiujuan XIA ; Hao CHENG ; Yingmin JIA ; Guoqing ZHAO ; Jinchun YAN ; Bo CHEN
Chinese Medical Journal 2024;137(2):200-208
Background::Atopic dermatitis (AD) affects approximately 10% of adults worldwide. CM310 is a humanized monoclonal antibody targeting interleukin-4 receptor alpha that blocks interleukin-4 and interleukin-13 signaling. This trial aimed to evaluate the efficacy and safety of CM310 in Chinese adults with moderate-to-severe AD.Methods::This multicenter, randomized, double-blind, placebo-controlled, phase 2b trial was conducted in 21 medical institutions in China from February to November 2021. Totally 120 eligible patients were enrolled and randomized (1:1:1) to receive subcutaneous injections of 300 mg CM310, 150 mg CM310, or placebo every 2 weeks for 16 weeks, followed by an 8-week follow-up period. The primary endpoint was the proportion of patients achieving ≥75% improvement in the Eczema Area and Severity Index (EASI-75) score from baseline at week 16. Safety and pharmacodynamics were also studied.Results::At week 16, the proportion of EASI-75 responders from baseline was significantly higher in the CM310 groups (70% [28/40] for high-dose and 65% [26/40] for low-dose) than that in the placebo group (20%[8/40]). The differences in EASI-75 response rate were 50% (high vs. placebo, 95% CI 31%–69%) and 45% (low vs. placebo, 95% CI 26%–64%), with both P values <0.0001. CM310 at both doses also significantly improved the EASI score, Investigator’s Global Assessment score, daily peak pruritus Numerical Rating Scale, AD-affected body surface area, and Dermatology Life Quality Index compared with placebo. CM310 treatment reduced levels of thymus and activation-regulated chemokine, total immunoglobulin E, lactate dehydrogenase, and blood eosinophils. The incidence of treatment-emergent adverse events (TEAEs) was similar among all three groups, with the most common TEAEs reported being upper respiratory tract infection, atopic dermatitis, hyperlipidemia, and hyperuricemia. No severe adverse events were deemed to be attributed to CM310. Conclusion::CM310 at 150 mg and 300 mg every 2 weeks demonstrated significant efficacy and was well-tolerated in adults with moderate-to-severe AD.Trial Registration::ClinicalTrials.gov, NCT04805411.
8.Polydatin affects malignant biological behaviors and DDP chemosensitivity of thyroid cancer 8505C cells through the Hippo/YAP pathway
CAO Jianzhong ; HUANG Jinshi ; DING Yating
Chinese Journal of Cancer Biotherapy 2024;31(3):224-230
[摘 要] 目的:探究虎杖苷通过Hippo/Yes相关蛋白(YAP)通路对人甲状腺癌8505C细胞的恶性生物学行为和顺铂(DDP)敏感性的影响。方法:体外培养8505C细胞,构建其DDP耐药细胞8505C/DDP,用CCK-8法检测0、25、50、75、100 nmol/L虎杖苷处理8505C和8505C/DDP细胞的增殖能力,以筛选虎杖苷的最佳作用浓度。将8505C细胞分为对照组、虎杖苷组、空载组、虎杖苷+YAP1过表达组;将8505C/DDP细胞分为对照组、DDP组、DDP+虎杖苷组、DDP+空载组、DDP+虎杖苷+YAP1过表达组。WB法检测各组8505C细胞中Hippo/YAP通路[YAP1、转录辅激活因子(TAZ)]和EMT(E-cadherin、N-cadherin)相关蛋白,8505C/DDP细胞中YAP1、TAZ、耐药相关蛋白[P-糖蛋白(P-gp)、多药耐药相关蛋白1(MRP1)]、凋亡相关蛋白(C-caspase-3、BAX、Bcl-2)的表达。Transwell小室和细胞划痕实验分别检测各组8505C、8505C/DDP细胞的侵袭、迁移能力。结果:虎杖苷可显著抑制8505C细胞的增殖活性(P<0.05)明显抑制8505C细胞中YAP1、TAZ蛋白、N-cadherin的表达(均P<0.05),提升E-caderin蛋白的表达(P<0.05),显著抑制8505C细胞的迁移和侵袭能力(均P<0.05),而8505C/DDP细胞对低浓度的虎杖苷具有耐药性(P<0.05);过表达YAP1则可逆转虎杖苷对8505C细胞的影响。50 nmol/L虎杖苷明显抑制DDP处理的8505C/DDP细胞中YAP1、TAZ、P-gp、MRP1、Bcl-2的蛋白的表达(均P<0.05),提升cleaved caspase-3、BAX蛋白的表达(均P<0.05)并诱导其细胞凋亡(P<0.05),过表达YAP1则可逆转虎杖苷对8505C/DDP细胞的影响。结论:虎杖苷抑制Hippo/YAP信号通路,从而抑制8505C细胞的恶性生物学行为和增强其对的DDP敏感性。
9.Research progress regarding CYP3A gene family in gastric cancer
Qi JIA ; Qingsong DING ; Kangmei SHAO ; Jianzhong DANG ; Fan ZHANG
Journal of Central South University(Medical Sciences) 2023;48(12):1874-1881
Cytochrome P450 family 3 subfamily A(CYP3A),a major member of cytochrome P450(CYP)family,is one of the most important drug metabolizing enzymes in human.CYP3A includes 4 gene subtypes(CYP3A4,CYP3A5,CYP3A7,and CYP3A43),which is involved in 60%of drug metabolism in the human.It is not only widely distributed in normal tissues,but also significantly overexpressed in various tumor tissues.Recently,CYP3A has attracted great attention due to its involvement in the progression from chronic atrophic gastritis to gastric cancer,as well as the differential metabolism and resistance of chemotherapeutic drugs.Targeting CYP3A gene mediated-prodrug provides new ideas for the treatment of gastric cancer and is expected to become a new target for the diagnosis and treatment of gastric cancer.
10.Epidemiology of urticaria in China: a population-based study
Jiaqing LI ; Dandan MAO ; Shuoshuo LIU ; Ping LIU ; Jing TIAN ; Chenhong XUE ; Xiaojing LIU ; Ruiqun QI ; Bingxue BAI ; Jianjun NIE ; Siqi YE ; Yu WANG ; Yuye LI ; Qing SUN ; Juan TAO ; Shuping GUO ; Hong FANG ; Jianqin WANG ; Qiri MU ; Quanzhong LIU ; Yan DING ; Jianzhong ZHANG
Chinese Medical Journal 2022;135(11):1369-1375
Background::Urticaria is a common skin disease characterized by episodes of wheals, and it has a negative effect on patients’ quality of life. Large-scale population-based epidemiological studies of urticaria are scarce in China. The aim of this survey was to determine the prevalence, clinical forms, and risk factors of urticaria in the Chinese population.Methods::This survey was conducted in 35 cities from 31 provinces, autonomous regions, and municipalities of China. Two to three communities in each city were selected in this investigation. Participants completed questionnaires and received dermatological examinations. We analyzed the prevalence, clinical forms, and risk factors of urticaria.Results::In total, 44,875 questionnaires were distributed and 41,041 valid questionnaires were collected (17,563 male and 23,478 female participants). The lifetime prevalence of urticaria was 7.30%, with 8.26% in female and 6.34% in male individuals ( P < 0.05). The point prevalence of urticaria was 0.75%, with 0.79% in female and 0.71% in male individuals ( P < 0.05). Concomitant angioedema was found in 6.16% of patients. Adults had a higher prevalence of urticaria than adolescents and children. Living in urban areas, exposure to pollutants, an anxious or depressed psychological status, a personal and family history of allergy, thyroid diseases, and Helicobacter pylori infection were associated with a higher prevalence of urticaria. Smoking was correlated with a reduced risk of urticaria. Conclusion::This study demonstrated that the lifetime prevalence of urticaria was 7.30% and the point prevalence was 0.75% in the Chinese population; women had a higher prevalence of urticaria than men. Various factors were correlated with urticaria.

Result Analysis
Print
Save
E-mail